Skip to content

CNS Drugs

ISSN 1179-1934

28 papers in the library · 714 citations · publishing 2013-2026

Papers

Sort Most recent Most cited

Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.

CNS Drugs May 1, 2021 Ioline D. Henter, Lawrence T. Park, Carlos A. Zarate

The efficacy of standard antidepressants is limited for many patients with mood disorders such as major depressive disorder (MDD) and bipolar depression, underscoring the urgent need to develop novel therapeutics. Both clinical and preclinical studies have implicated glutamatergic system dysfunction in the pathophysiology of mood disorders. In particular, rapid reductions in depressive symptoms...

Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies

CNS Drugs August 17, 2020 Joost J. Breeksema, Alistair Niemeijer, Erwin Krediet et al. 217 citations

This review demonstrates how qualitative research of psychedelic treatments can contribute to distinguishing specific features of specific substances, and carry otherwise undiscovered implications for the treatment of specific psychiatric disorders.

Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence.

CNS Drugs April 1, 2013 Jerome Sarris, Erica Mcintyre, David A Camfield 154 citations

Research in the area of herbal psychopharmacology has revealed a variety of promising medicines that may provide benefit in the treatment of general anxiety and specific anxiety disorders. However, a comprehensive review of plant-based anxiolytics has been absent to date. Thus, our aim was to provide a comprehensive narrative review of plant-based medicines that have clinical and/or preclinical...